Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by BPGbio, Inc.

BPGbio Unveils Research on the Identification of Novel Pancreatic Cancer Patient Subtypes at ASCO GI 2025 Paving the Way for Tailored Treatment
From BPGbio, Inc.
Via Business Wire
BPGbio to Present Transformative Immuno-Oncology Research on BPM31510 and BRG399 at SITC 2024
From BPGbio, Inc.
Via Business Wire
CORRECTING and REPLACING BPGbio Receives FDA Rare Pediatric Disease Designation for its Investigational Treatment for Epidermolysis Bullosa
From BPGbio, Inc.
Via Business Wire
BPGbio to Present New Data on Novel Glioblastoma Therapies at SNO 2024
From BPGbio, Inc.
Via Business Wire
BPGbio CEO Niven R. Narain to Present at Google’s Inaugural Cancer AI Symposium
From BPGbio, Inc.
Via Business Wire
BPGbio to Present Novel E2-based Targeted Protein Degradation Program at TPD and Induced Proximity Summit
From BPGbio, Inc.
Via Business Wire
BPGbio to Present New Data on BPM31510 and Novel Quinomics Technology for Treatment of Primary CoQ10 Deficiency at MitoCon 2024
From BPGbio, Inc.
Via Business Wire
BPGbio to Present on E2-based Approach to Targeted Protein Degradation at US Pharma Partnering Summit
From BPGbio, Inc.
Via Business Wire
BPGbio CEO Dr. Niven R. Narain Honored as PharmaVoice 100 Winner for Pioneering Work in AI-Driven Drug Discovery
From BPGbio, Inc.
Via Business Wire
BPGbio and University of Oxford Enter into Strategic Collaboration Focused on Breakthrough E2-based Protein Degradation Research in Oncology and CNS Diseases
From BPGbio, Inc.
Via Business Wire
BPGbio to Present Novel Drug Target for Huntington’s Disease and AI Discovered Biomarkers for Alzheimer’s Disease at Society for Neuroscience 2024
From BPGbio, Inc.
Via Business Wire
BPGbio Receives FDA Rare Pediatric Disease Designation for its Potential Treatment for Primary Coenzyme Q10 Deficiency
From BPGbio, Inc.
Via Business Wire
BPGbio Presents Phase 2b BPM31510 Glioblastoma Trial-in-Progress Update and Pioneering Comprehensive Quinomics Assessment at the ESMO Congress 2024
From BPGbio, Inc.
Via Business Wire
BPGbio to Present on its First-in-Class E2-based Approach to Targeted Protein Degradation at 15th Annual Drug Innovation Forum
From BPGbio, Inc.
Via Business Wire
BPGbio to Present Research and Pipeline Advancements on Mitochondrial Medicine at EBEC 2024
From BPGbio, Inc.
Via Business Wire
BPGbio Appoints Esteemed Cancer Researcher Dr. Dipanjan Chowdhury to Scientific Advisory Board
From BPGbio, Inc.
Via Business Wire
BPGbio Sponsors Mitochondrial Medicine 2024 Conference
From BPGbio, Inc.
Via Business Wire
BPGbio Brings Late Clinical Stage Rare Disease and Oncology Assets to US and EU Pharma Partnering Summits
From BPGbio, Inc.
Via Business Wire
BPGbio Presents Key Advances in its Oncology Pipeline related to the NAi Interrogative Biology Platform
From BPGbio, Inc.
Via Business Wire
Lincoln Property Company, BPGbio, and Cresa Announce 70,000-sq.-ft. Lease at 300 Third Avenue in Waltham
From BPGbio, Inc.
Via Business Wire
BPGbio Appoints Ritesh Srivastava as General Counsel
From BPGbio, Inc.
Via Business Wire
BPGbio Presents Updated Phase 2a Clinical Results Demonstrating Benefit of BPM31510 in Combination with Chemotherapy in Pancreatic Cancer at ASCO GI
From BPGbio, Inc.
Via Business Wire
BPGbio Announces Phase 2 BPM31510 Glioblastoma Trial-in-Progress Update at Society for Neuro-Oncology Annual Meeting
From BPGbio, Inc.
Via Business Wire
Leading AI-Powered Biopharma BPGbio Appoints Kenin Spivak to Board of Directors
From BPGbio, Inc.
Via Business Wire
BPGbio Wins 2023 BioTech Breakthrough Award for Therapeutics Platform of The Year
From BPGbio, Inc.
Via Business Wire
BPGbio Highlights AI-Developed Late-Stage Therapeutics Assets at 8th Annual INV€$TIVAL Showcase in Partnership with Jefferies
From BPGbio, Inc.
Via Business Wire
BPGbio to Share Updates in Development of Late-Stage AI-Developed Therapeutic Pipeline at the Pharma Partnering Summit
From BPGbio, Inc.
Via Business Wire
BPGbio Announces Promising Readout from Phase 2a Trial Evaluating BPM 31510 IV for Pancreatic Cancer
From BPGbio, Inc.
Via Business Wire
BPGbio Appoints Vijay Modur, M.D., Ph.D., as SVP & Chief Medical Officer
From BPGbio, Inc.
Via Business Wire
BPGbio Announces Commercial Availability of NAi, BPGbio’s Pioneering Interrogative Biology Platform
From BPGbio, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.